KLTO (Klotho Neurosciences) Cash-to-Debt : 0.34 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Klotho Neurosciences's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.34.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Klotho Neurosciences couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Klotho Neurosciences's Cash-to-Debt or its related term are showing as below:

KLTO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.14 Max: No Debt
Current: 0.34

During the past 2 years, Klotho Neurosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.14.

KLTO's Cash-to-Debt is ranked worse than
87.05% of 1483 companies
in the Biotechnology industry
Industry Median: 7.42 vs KLTO: 0.34

Klotho Neurosciences Cash-to-Debt Historical Data

The historical data trend for Klotho Neurosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Klotho Neurosciences Cash-to-Debt Chart

Klotho Neurosciences Annual Data

Trend

Dec21

Dec22

Cash-to-Debt

No Debt

0.06

Klotho Neurosciences Quarterly Data
	Dec21	Jun22	Dec22	Jun23	Sep23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial			0.03	N/A	0.02	0.22	0.34

Competitive Comparison of Klotho Neurosciences's Cash-to-Debt

For the Biotechnology subindustry, Klotho Neurosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Klotho Neurosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Klotho Neurosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Klotho Neurosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.076	/	(1.348	+	0)
	=	0.06

Klotho Neurosciences's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.051	/	(0.151	+	0)
	=	0.34

Klotho Neurosciences (NAS:KLTO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Klotho Neurosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Klotho Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

13576 Walnut Street, 12th Floor, Omaha, NE, USA, 68144

Website

https://www.klothoneuro.com

Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.